HEALTHCARE RESOURCE UTILIZATION AND COSTS ASSOCIATED WITH SYSTEMIC INFLAMMATION IN PATIENTS WITH CORONARY HEART DISEASE AND CHRONIC KIDNEY DISEASE: A RETROSPECTIVE COHORT STUDY
Author(s)
Danqing Qian, MPA1, MIN HU, PhD2.
1Fudan University, Shanghai, China, 2Professor, Fudan University, Shanghai, China.
1Fudan University, Shanghai, China, 2Professor, Fudan University, Shanghai, China.
Presentation Documents
OBJECTIVES: To evaluate the association of systemic inflammation (SI) with healthcare resource utilization (HCRU) and direct medical costs in patients with coronary heart dis-ease (CHD) and stage 3-4 chronic kidney disease (CKD).
METHODS: In this retrospective cohort study, we analyzed electronic medical records of adults hospitalized in 2023 at a tertiary hospital in Beijing, China, with confirmed CHD and stage 3-4 CKD. Patients were classified into SI (hsCRP >2 mg/L) or non-SI (hsCRP ≤2 mg/L) groups and followed for 12 months. HCRU outcomes were analyzed using negative binomial regression, and direct medical costs using a Heckman selection model.
RESULTS: Among 200 included patients (SI: n=112; non-SI: n=88), SI was associated with significantly increased all-cause HCRU, including higher annual total visits (IRR=1.46; 95% CI 1.05-2.04) and outpatient visits (IRR=1.52; 95% CI 1.01-2.28), as well as longer length of stay per admission (IRR=1.45; 95% CI 1.10-1.91). Cardiovascu-lar-specific HCRU was even more pronounced, with IRR of 4.22 (95% CI 1.01-17.66) for annual total visits and 4.73 (95% CI 1.01-22.23) for hospitalizations. Correspond-ingly, the SI group incurred significantly higher annual medical costs for both all-cause (¥92,563 vs. ¥34,849; p<0.001) and cardiovascular-specific costs (¥12,264 vs. ¥1,263; p=0.002). Treating hsCRP as a continuous variable, each 1 mg/L increase was associated with an increase in all-cause annual total costs (¥802.99; p<0.001).
CONCLUSIONS: In patients with CHD and CKD, systemic inflammation is strongly as-sociated with substantially increased healthcare resource utilization and direct medical costs. Our findings quantify this burden, showing near tripling of all-cause costs and a more than fourfold increase in cardiovascular-specific resource use. These results un-derscore the potential economic and clinical benefits of evaluating inflammation-targeted strategies in this high-risk population.
METHODS: In this retrospective cohort study, we analyzed electronic medical records of adults hospitalized in 2023 at a tertiary hospital in Beijing, China, with confirmed CHD and stage 3-4 CKD. Patients were classified into SI (hsCRP >2 mg/L) or non-SI (hsCRP ≤2 mg/L) groups and followed for 12 months. HCRU outcomes were analyzed using negative binomial regression, and direct medical costs using a Heckman selection model.
RESULTS: Among 200 included patients (SI: n=112; non-SI: n=88), SI was associated with significantly increased all-cause HCRU, including higher annual total visits (IRR=1.46; 95% CI 1.05-2.04) and outpatient visits (IRR=1.52; 95% CI 1.01-2.28), as well as longer length of stay per admission (IRR=1.45; 95% CI 1.10-1.91). Cardiovascu-lar-specific HCRU was even more pronounced, with IRR of 4.22 (95% CI 1.01-17.66) for annual total visits and 4.73 (95% CI 1.01-22.23) for hospitalizations. Correspond-ingly, the SI group incurred significantly higher annual medical costs for both all-cause (¥92,563 vs. ¥34,849; p<0.001) and cardiovascular-specific costs (¥12,264 vs. ¥1,263; p=0.002). Treating hsCRP as a continuous variable, each 1 mg/L increase was associated with an increase in all-cause annual total costs (¥802.99; p<0.001).
CONCLUSIONS: In patients with CHD and CKD, systemic inflammation is strongly as-sociated with substantially increased healthcare resource utilization and direct medical costs. Our findings quantify this burden, showing near tripling of all-cause costs and a more than fourfold increase in cardiovascular-specific resource use. These results un-derscore the potential economic and clinical benefits of evaluating inflammation-targeted strategies in this high-risk population.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE216
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Cardiovascular Disorders (including MI, Stroke, Circulatory)